Rani Therapeutics (NASDAQ:RANI) Earns Buy Rating from Analysts at Rodman & Renshaw
Rodman & Renshaw began coverage on shares of Rani Therapeutics (NASDAQ:RANI – Free Report) in a research report released on Thursday, Marketbeat Ratings reports. The brokerage issued a buy rating and a $10.00 target price on the stock. RANI has been the subject of a number of other reports. HC Wainwright lifted their price target […]
More Stories
GoalVest Advisory LLC Sells 3,237 Shares of Southern Copper Co. (NYSE:SCCO)
GoalVest Advisory LLC lowered its stake in shares of Southern Copper Co. (NYSE:SCCO – Free Report) by 16.4% during the...
Mutual of America Capital Management LLC Sells 7,761 Shares of Essent Group Ltd. (NYSE:ESNT)
Mutual of America Capital Management LLC lessened its holdings in Essent Group Ltd. (NYSE:ESNT – Free Report) by 3.4% during...
CIBC Asset Management Inc Buys 3,742 Shares of Coca-Cola Europacific Partners PLC (NASDAQ:CCEP)
CIBC Asset Management Inc lifted its stake in Coca-Cola Europacific Partners PLC (NASDAQ:CCEP – Free Report) by 3.8% during the...
Kovack Advisors Inc. Has $205,000 Stock Position in Alibaba Group Holding Limited (NYSE:BABA)
Kovack Advisors Inc. lessened its holdings in Alibaba Group Holding Limited (NYSE:BABA – Free Report) by 94.5% during the 3rd...
Schneider Downs Wealth Management Advisors LP Acquires Shares of 8,200 The Baldwin Insurance Group, Inc. (NASDAQ:BRP)
Schneider Downs Wealth Management Advisors LP purchased a new position in The Baldwin Insurance Group, Inc. (NASDAQ:BRP – Free Report)...
Vaughan Nelson Investment Management L.P. Purchases 152,030 Shares of Beacon Roofing Supply, Inc. (NASDAQ:BECN)
Vaughan Nelson Investment Management L.P. raised its holdings in Beacon Roofing Supply, Inc. (NASDAQ:BECN – Free Report) by 18.7% during...